Stelara 90 MG/ML syringeml
Ended Awarded
- Contract number
- SPE2DR26FCRG1
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $49,752
Award facts
- Contract value 100% obligated
- $49,752.39 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order on November 4, 2025, by the Defense Logistics Agency for STELARA 90 MG/ML syringes valued at $49,752.39 under a firm fixed-price contract structure. This delivery order was issued without a set-aside designation, demonstrating the company's competitive capability in unrestricted federal procurement. The award is associated with DMS Pharmaceutical Group's larger Indefinite Delivery Contract (IDC) under the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion acquisition strategy that positions the company as one of multiple regional prime vendor contractors authorized to supply pharmaceutical products and medical consumables to Department of Defense healthcare facilities worldwide.
Under the PPV-G GEN V contract designated SPE2DR, awarded on November 13, 2025, with a $499.9 billion ceiling value and completion date of December 31, 2036, DMS Pharmaceutical Group serves as a critical supplier of branded and generic prescription medications, biologics, vaccines, specialty pharmaceuticals, and medical consumables to support recurring medical supply needs across the military healthcare system globally. The company maintains no identified subcontractor relationships, operating as a direct supplier to the Defense Logistics Agency's Medical Supply Chain division. This delivery order for STELARA, an immunosuppressant biologic agent, exemplifies the company's role in fulfilling specialized pharmaceutical requirements for Department of Defense operations, with the ultimate completion date of November 26, 2025.
Quick answers
Who was awarded contract SPE2DR26FCRG1?
SPE2DR26FCRG1 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on November 4, 2025.
How much is contract SPE2DR26FCRG1 worth?
The government has obligated $49,752 on SPE2DR26FCRG1.
Is contract SPE2DR26FCRG1 an order under another contract?
Yes. SPE2DR26FCRG1 is a delivery order under SPE2DR25D9168, an indefinite delivery contract.
Was contract SPE2DR26FCRG1 competed?
The extent of competition for SPE2DR26FCRG1 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award